Pipeline of Novel Drugs
We have developed a rich pipeline of 21+ novel drugs which are next generation, substrate-specific p38α kinase immunomodulators, and 5 novel, next generation, substrate-specific ERK 1/2 immunomodulators to provide safe, selective, and effective therapies for rare and inflammatory diseases.
Our NextGen drugs are immunomodulatory and target specific inflammatory substrates while avoiding anti-inflammatory substrates in contrast to the first generation compounds, which were immunosuppressive, non-specific, and failed for safety or efficacy reasons.
While we are elevating our Lead Compound (Gen-1124) to the next level, we are simultaneously making progress on Indications 2 and 3.
If rare and inflammatory diseases are your areas of interest, do reach out to us to explore synergies via partnership.